Stock Price & Analysis

Based on the analysis of Kymera Therapeutics (KYMR), the stock presents a mixed outlook. While analysts maintain a Moderate Buy rating with a target price of $60.38, recent insider selling activity and technical indicators suggest caution. Hold the stock as upside potential exists, but wait for clearer market signals before making a move.

The price prediction for KYMR stock in 2025 is $58 per share. This forecast is based on analyst consensus, with several firms maintaining a Buy rating and highlighting the company's promising pipeline, particularly its STAT6 degrader program and collaborations with major pharmaceutical companies. However, risks such as insider selling activity and clinical trial uncertainties could impact the stock's performance.

The S1 support level for KYMR Stock is $32.08 ,The R1 resistant level for KYMR Stock is $35.11.

As of the end of day on 2025-03-21, the price of KYMR Stock was $31.91.

The target price for KYMR Stock according to analyst rating is 59.54, with the highest price target at 97.00 and the lowest at 49.00. Analysts have a Strong Buy rating on KYMR Stock overall.

The market cap of KYMR is $2.1B.

Analysis and Insights

To determine whether Kymera Therapeutics (KYMR) is overvalued, we analyze key valuation metrics, analyst sentiment, and recent price action.

Valuation Analysis:

Kymera Therapeutics currently trades at $34.075, with a price-to-sales (P/S) ratio of 3.12 and a price-to-book (P/B) ratio of 0.88. The EV/EBITDA ratio is elevated at 64.13, suggesting the stock may be richly valued relative to its earnings. However, the P/B ratio indicates the stock may be undervalued relative to its book value.

Analyst Sentiment:

Analysts maintain a Strong Buy consensus with an average price target of $60.38, implying significant upside potential. Recent ratings include a $52 target from Citigroup and a $60 target from HC Wainwright, reflecting confidence in the company's pipeline and strategic position.

Price Action and Volatility:

The stock has experienced volatility, trading between $29.24 and $53.27 over the past year. Recent price action shows a slight decline, potentially reflecting near-term uncertainties despite long-term growth prospects.

Conclusion:

While the high EV/EBITDA ratio raises concerns about valuation, the low P/B ratio and analyst consensus suggest the stock is not significantly overvalued. Insider selling and market sentiment contribute to short-term volatility, but the overall outlook remains positive.

Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

By 2030, KYMR stock is predicted to reach $100 per share, driven by its promising pipeline progress in atopic dermatitis and asthma treatments, with clinical trials set to commence in late 2025 and early 2026. The company's strategic collaborations, such as with Sanofi, and its strong cash runway into mid-2027, position it for significant growth in the biotech sector.

KYMR has a total of 187 employees.